ARTICLE | Clinical News
Phase III data for ATLN's tezosentan
February 13, 2001 8:00 AM UTC
Actelion and partner Genentech (DNA) said that in a pivotal trial of ATLN's intravenous dual endothelial receptor antagonist tezosentan, the compound produced positive hemodynamic results in 292 patie...